Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non–small-cell lung cancer xenograft models

BACKGROUND: Non–small-cell lung cancer (NSCLC) is categorized into various histologic subtypes that play an important role in prognosis and treatment outcome. We investigated the antitumor activity of motesanib, a selective antagonist of vascular endothelial growth factor receptors (VEGFR) 1, 2, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Coxon, Angela, Ziegler, Beth, Kaufman, Stephen, Xu, Man, Wang, Hongyu, Weishuhn, Dawn, Schmidt, Joanna, Sweet, Heather, Starnes, Charlie, Saffran, Douglas, Polverino, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515409/
https://www.ncbi.nlm.nih.gov/pubmed/22992329
http://dx.doi.org/10.1186/1476-4598-11-70

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3515409/
https://www.ncbi.nlm.nih.gov/pubmed/22992329
http://dx.doi.org/10.1186/1476-4598-11-70

Ejemplares similares